Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$2.44 USD
-0.07 (-2.79%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $2.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EDIT 2.44 -0.07(-2.79%)
Will EDIT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDIT
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Other News for EDIT
Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
Editas Medicine Reaches Analyst Target Price
Editas Medicine (EDIT) Strengthens Despite FDA Division Shakeup
Gene editors steady despite latest leadership shake-up at FDA
JonesTrading Sticks to Their Hold Rating for Editas Medicine (EDIT)